Back to search results

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Sclerosis · Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stanford Multiple Sclerosis Center, Palo Alto, California, United States

    Contact: Study coordinator (Emma Martinez, BA) · eam1@stanford.edu · 650-387-5907
    Contact: Principal Investigator (Jeffrey Dunn, MD)
    Everett Meyer, MD (Sub-investigator)
    Robert Lowsky, MD (Sub-investigator)
    Saurabh Dahiya, MD (Sub-investigator)
    Jamie McDonald, MD, MS (Sub-investigator)
    Garrett Timmons, MD (Sub-investigator)
Study leads

  • Jeffrey Dunn, MD

    Principal Investigator

    Stanford University

View source on ClinicalTrials.gov(opens in a new tab)